ESMO 2019 | PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC

Maha Hussain

Maha Hussain, MBChB, FACP, FASCO, of Northwestern University Feinberg School of Medicine, Chicago, IL, presents the results of the phase 3 PROfound study of olaparib vs. enzalutamide or abiraterone for metastatic castration-resistant prostate cancer HRR gene alterations. Next, Ignacio Duran, MD, PhD, Marques de Valdecilla University Hospital, Santander, Spain, discussing the impact of these data.

Share this video